Alzheimer’s drugs: Does reducing amyloid work?
暂无分享，去创建一个
[1] Justin S. Sanchez,et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography , 2021, Science Translational Medicine.
[2] D. Berry,et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.
[3] B. Hyman,et al. Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.
[4] M. Slama,et al. Hereditary transthyretin amyloidosis: current treatment , 2020, Current opinion in neurology.
[5] B. Matthews,et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials , 2019, Alzheimer's & dementia.